CASE REPORTS

ONE CASE OF TOXIC EPIDERMAL NECROLYSIS AFTER TREATMENT WITH BELIMUMAB IN A PATIENT WITH SYSTEMIC LUPUS ERYTHEMATOSUS

Madalina Duna¹, Dinu Valentin Balanescu¹, Cristina Iosif², Narcis Copca³, Denisa Predeteanu¹, Ruxandra Ionescu¹

¹Department of Internal Medicine and Rheumatology, Sfanta Maria Clinical Hospital, Bucharest, Romania
²Department of Pathology, Sfanta Maria Clinical Hospital, Bucharest, Romania
³Department of Surgery, Sfanta Maria Clinical Hospital, Bucharest, Romania

Abstract

Belimumab is a human immunoglobulin G1-lambda-1 (IgG1-λ) monoclonal antibody that targets the soluble BlyS human protein, also known as B-cell activating factor (BAFF) approved for the treatment of systemic lupus erythematosus (SLE). Serious and sometimes fatal infections have been reported in patients receiving novel immunosuppressive agents, including belimumab. Thus, physicians should exercise caution when considering belimumab in patients with SLE. A 50-year-old woman with SLE presented with a severe, diffuse rash two months after initiating treatment with belimumab. A skin biopsy revealed epidermal necrolysis with keratinocyte detachment and apoptosis in the basal layer of the epidermis, suggestive for toxic epidermal necrolysis (TEN). Belimumab was discontinued and 500 mg of pulse IV methylprednisolone therapy every day for 3 days were administered, with resolution of the skin lesions in the following days. To the best of our knowledge, this is the first case of belimumab-associated TEN.

Keywords: systemic lupus erythematosus, autoimmune disease, toxic epidermal necrolysis, belimumab

INTRODUCTION

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease affecting multiple organs, with a variable severity that can range from mild to life-threatening (1). People with SLE that receive proper treatment and preventive strategies for complications can have a significantly improved function, disease course, and quality of life (2). The treatment of SLE consists primarily of immunosuppressive drugs, most often hydroxychloroquine and corticosteroids. Both the European Medicines Agency (4) and the United States Food and Drug Administration (FDA) (3) approved belimumab for the treatment of SLE in 2011, thus becoming the first targeted therapy for this disease. Before belimumab, the last drug to be approved by the FDA for the treatment of SLE was hydroxychloroquine in 1955 (5).

Belimumab is a fully humanized IgG1γ monoclonal antibody directed against the soluble B lymphocyte stimulator (BlyS) (6). It is the only approved biologic agent for the treatment of SLE. It is indicated as an add-on therapy for the treatment of adult patients with active, autoantibody-positive SLE, who have previously received standard therapy. Belimumab is generally well-tolerated, with common adverse effects including infections, infusion reactions, hypersensitivity, headache, nausea, and fatigue.

We present the case of a 50-year-old woman with SLE who experienced a severe cutaneous adverse reaction two months after initiating treatment with belimumab.

Corresponding author:
Madalina Duna, MD, Department of Internal Medicine and Rheumatology, „Sfanta Maria” Clinical Hospital, 37-39 Ion Mihalache Boulevard, Bucharest, Romania
E-mail: madalina.duna@yahoo.com
CASE REPORT

A 50-year-old woman diagnosed with SLE 2 years prior presented for the sudden onset of a diffuse, scaly, erythematous rash. At the onset of the disease in May 2017, the patient presented with a facial rash and arthritis of the hands. Laboratory findings at that time included hypochromic microcytic anemia, positive inflammatory markers, hypocomplementemia, hyperimmunoglobulinemia, and positive antinuclear antibodies (ANA) and anti-double stranded DNA (anti-dsDNA) antibodies. An ultrasound of the hands revealed synovitis in at least 3 metacarpophalangeal (MCP) joints with grade 2 intra-articular Doppler signal and synovitis of the distal interphalangeal (DIP) joint of the left index finger. The patient met 6/16 points of the revised SLICC criteria (2015) for the SLE diagnosis. Treatment with 400 mg of hydroxychloroquine daily and low-dose (10 mg daily) corticosteroids was initiated. After one month of treatment with hydroxychloroquine, she developed a diffuse rash. Hydroxychloroquine was discontinued and 100 mg of azathioprine (AZA) daily was started. Due to the persistent skin lesions, she received dapsone as consolidation therapy. In December 2018, she presented with papulo-squamous lesions on the face, upper torso, and upper back (Fig. 1a,b). Laboratory tests showed hypochromic microcytic anemia (hemoglobin, 9.5 g/dl), lymphopenia, hypocomplementemia, and high-titers of ANA and anti-dsDNA antibodies. A 24-hour urine protein test was performed to rule out renal involvement and was normal (754 mg protein/24 hours). An electrocardiogram, abdominal ultrasound and chest X-ray were normal. Transthoracic echocardiography revealed a small amount (4 mm) of pericardial fluid.

The ultrasound of the hands showed bilateral extensor tenosynovitis (Fig. 2).

Subacute cutaneous lupus was suspected and a skin biopsy was performed. The pathology exam (Fig. 3) showed vacuoles at the level of the basal keratinocytes and perivascular lymphoplasmacytic inflammatory infiltrate, suggestive of subacute SLE. The patient was treated with 250 mg of pulse IV methylprednisolone therapy for four consecutive days, with resolution of the skin lesions. However, the patient had an intense disease activity, with a SELENA-SLEDAI score of 20.

At that moment, the patient met the criteria for therapy with belimumab: age >18, a clinical diagnosis of SLE, active disease, positive autoantibodies, stable SLE treatment with glucocorticoids. She received the first 3 loading doses 10 mg/kg (days 0, 14, 28) of belimumab in January 2019, and another dose four weeks later. Following the last infusion, she developed a diffuse erythematous, bullous rash with rapid coalescence and extensive desquamation (Fig. 4a, b) and a positive Nikolsky sign.

Laboratory findings were normal, with the exception of hypocomplementemia, which was not dif-
different from her “baseline” since diagnosis. Musculoskeletal ultrasonography of the hands and wrist revealed tenosynovitis of the extensor tendons.

Dermatology was consulted and suspected a drug-related reaction rather than SLE flare. Another skin biopsy was performed, revealing epidermal necrosis with detachment and keratinocyte apoptosis in the basal layer of the epidermis (Fig. 5a, b) suggestive for toxic epidermal necrolysis (TEN). Anamnestic, clinical and paraclinical findings were consistent with TEN.

Belimumab was immediately stopped and the patient was treated with pulse IV methylprednisolone therapy 500 mg for three consecutive days associated with gastric protection and potassium and vitamin D supplementation to prevent corticosteroids-induced adverse events. In the following three days, a progressive improvement of the skin reaction was noted. She was discharged a week later, with markedly improved aspect of the skin lesions (Fig. 6a, b). SLE treatment was changed to azathioprine 100 mg/day and a tapering medium dose (25 mg daily) of oral corticosteroids. This adverse event was reported to the Romanian National Medications Association.

Laboratory findings showed satisfactory laboratory tests improvement (resolution hemolytic anemia and lymphopenia), being present only hypocomplementemia. This time, the dermatologist stated

**FIGURE 2. Ultrasound of the hands showing bilateral extensor tenosynovitis**

**FIGURE 3. Histopathological findings showing vacuolar alteration of the basal keratinocytes and perivascular lymphoplasmacytic inflammatory infiltrate**

**FIGURE 4a, b. Erytemato-bullous lesions with tendency to rapid coalescence and epidermal detachment**
for the adverse reaction to belimumab. Another skin biopsy was performed and it showed epidermal necrolysis with detachment and keratinocyte apoptosis in the basal layer of the epidermis (Fig. 5a, b) suggestive for toxic epidermal necrolysis (TEN).

TEN is a potentially life-threatening dermatologic disorder characterized by widespread erythema, necrosis, and bullous detachment of the epidermis and mucous membranes, resulting in exfoliation and possible sepsis and/or death (7). The average report-
ed mortality rate of TEN is 25-35%; it can be even higher in elderly patients and those with a large surface area of epidermal detachment (8). A serious cutaneous reaction is more likely to occur during the first 2 months of treatment (9).

The management concentrate on resuscitative and supportive strategies with the primary concern that of avoiding infection. The general measures include immediate withdrawal of all the suspected drugs is the key to the management of TEN (10).

**DISCUSSION**

TEN is a potentially life-threatening dermatologic disorder characterized by widespread erythema, necrosis, and bullous detachment of the epidermis and mucous membranes, resulting in exfoliation and possible sepsis and/or death (7). The average reported mortality of TEN is 25-35%; it can be even higher in elderly patients and those with a large surface area of epidermal detachment (8). A serious cutaneous reaction is more likely to occur during the first 2 months of treatment (9). Management focuses on resuscitative and supportive strategies, with the primary goal of avoiding infection. General measures include immediate withdrawal of all suspected causative drugs is the key to the management of TEN (10). TEN occurs mostly after use of medications such as anticonvulsants, neuroleptics, antibiotics, antifungals, diuretics, non-hormonal anti-inflammatories, and analgesics.

Regarding skin reactions after belimumab, data from the clinical trials and long-term follow-up studies indicate that belimumab is generally well-tolerated (11). The rate of adverse events noted in various studies varies from 6% to 38%. The most common skin adverse effects include rash, cellulite.

**CONCLUSION**

To the best of our knowledge, this is the first report of TEN triggered by treatment with belimumab in a patient with SLE. Although rare, physicians should be aware of the possible skin reactions associated with novel biologic agents in SLE, such as belimumab.

**Compliance with ethical standards**

**Ethical approval.** All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

**Informed consent.** Informed consent was obtained from the patient presented in this work.

**REFERENCES**

1. Rees F, Doherty M, Grainge M et al. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999–2012. *Annals of the Rheumatic Diseases* 2016;75:136-141.
2. Dall’Era M. Systemic lupus erythematosus. In: Imboden JB, Hellman DB, Stone JH, (Eds). *Current Rheumatology Diagnosis and Treatment*. 3rd ed. New York, NY:McGraw-Hill; 2013.
3. Boyce EG, Fusco BE. Belimumab: Review of use in systemic lupus erythematosus. *Clin Ther*. 2012 May; 34(5):1006-22. Epub 2012 Mar 30.
4. Dubey AK, Handu SS, Dubey S, Sharma P, Sharma KK, Ahmed QM, Belimumab: First targeted biological treatment for systemic lupus erythematosus. *J Pharmacol Pharmacother*. 2011 Oct; 2(4):317-9.
5. Vilas-Boas A, Morais SA, Isenberg DA. Belimumab in systemic lupus erythematosus. *RMD Open*. 2015; 1(1):e000011.
6. Specchia ML, de Waure C, Gualano MR, Doria A, Turchetti G, Pippo L, Di Nardo F, Capizzi S, Cadeddu C, Kheirouci F, Iaccarino L, Pierotti F, Palia I, Veneziano MA, Gliubizzi D, Sferrazza A, Nicolotti N, Porcasi R, La Torre G, Di Pietro ML, Ricciardi W. Health technology assessment of belimumab: a new monoclonal antibody for the treatment of systemic lupus erythematosus. *Biomed Res Int*. 2014; 2014(1):704207.
7. Tiwari P, Panik R, Bhattacharya A, Ahirwar D, Chandy A. Toxic epidermal necrolysis: An update. *Asian Pac J Trop Dis*. 2013; 3(2):85–92. doi:10.1016/S2222-1808(13)60051-1
8. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. *N Engl J Med*. 1994 Nov 10; 331(19):1272-85.
9. Barvaliya MJ, Patel MK, Patel TK, Tripathi CB. Toxic epidermal necrolysis due to lamotrigine in a pediatric patient. *J Pharmacol Pharmacother*. 2012;3(4):336–338. doi:10.4103/0976-500X.103695
10. Tiwari, Prashant et al. Toxic epidermal necrolysis: An update. *Asian Pacific Journal of Tropical Disease* vol. 3,2 (2013): 85–92. doi:10.1016/S2222-1808(13)60051-1
11. Borchers AT, Lee JL, Naguwa SM, Cheema GS, Gershwin ME. Stevens-Johnson syndrome and toxic epidermal necrolysis. *Autoimmun Rev*. 2008;7:598–605. (PubMed) (Google Scholar) (Ref list)